Q-omics provides the consensus-scored RPL29P25 profile across patient tissues and cancer cell-line models. RPL29P25 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPL29P25 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, RPL29P25 RNA expression shows 6,159 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRP, and STAD as cancer lineages where RPL29P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P25 survival associations across molecular data types. RPL29P25 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P25 RNA expression–survival associations across cancer types. High RPL29P25 expression shows unfavorable associations in UCEC, THCA and LUSC, but favorable associations in LUAD, BRCA and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for RPL29P25 RNA expression.
This table summarizes RPL29P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P25 shows lower tumor expression in THCA and higher tumor expression in KIRP, COAD, LIHC, KIRC and PRAD. The KIRP box plot shows higher RPL29P25 RNA expression in tumor versus normal tissue (log2 FC = +0.149, t-test p = .021).
This table shows molecular features associated with RPL29P25 in patient tissues and cancer cell lines. In patient samples, RPL29P25 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
